← Back to searchRecruitingRecruiting
Improving Survival for Metastatic Lobular Breast Cancer (PLUMB Registry)
NCT05964504 · University of California, San Francisco
In plain English
Click the button to translate this study into plain language — what it is, who qualifies, and what participation looks like.
Official title
Improving Survival for Those With Metastatic Lobular Breast Cancer Through Development of the Multi-center PLUMB Registry-a Prospective Study of LobUlar Metastatic Breast Cancer
About this study
Primary Aims:
1. To evaluate the feasibility of developing a histologic based registry for participants living with metastatic lobular breast cancer.
2. To understand the natural history, treatment patterns, and overall survival in patients with metastatic ILC using modern, real-world data.
Secondary Aims:
1. To evaluate the correlation between imaging findings and disease progression.
2. To evaluate the correlation between ctDNA and disease progression.
3. To develop an ongoing platform for evaluating new imaging tools, tumor markers, and participant recruitment for clinical trials.
Outline:
Participants will be recruited to participate in the registry during a regularly scheduled clinic visit with their treating oncologist, and consented to participate at this time. At each evaluation time point, participants will have a blood draw performed. Participants will be followed until loss to follow up, death, or withdrawal from the registry.
Eligibility criteria
Inclusion Criteria:
1. Histologically confirmed invasive lobular carcinoma. Mixed lobular/ductal cancer is allowed.
2. Age \>=18 years
3. Any receptor subtype.
4. Ability to understand a written informed consent document, and the willingness to sign it.
Exclusion Criteria:
1. Stage I-III breast cancer.
2. Lack of lobular histology on tumor biopsy.
3. Other active cancer (prior treated cancer with no current evidence of disease is allowed).
Study design
Enrollment target: 12 participants
Age groups: adult, older_adult
Timeline
Starts: 2023-12-20
Estimated completion: 2036-02-28
Last updated: 2026-03-17
Interventions
Procedure: Blood Specimen
Primary outcomes
- • Feasibility of registry (Up to 2 years)
- • Proportion of patients with measurable versus unmeasurable disease (Up to 10 years)
- • Median Progression Free Survival Rate (Up to 10 years)
Sponsor
University of California, San Francisco · other
With: METAvivor Research and Support, Inc
Contacts & investigators
ContactAstrid Quirarte · contact · Astrid.Quirarte@ucsf.edu · 415-476-8390
InvestigatorRita Mukhtar, MD · principal_investigator, University of California, San Francisco
All locations (4)
University of California, San DiegoRecruiting
San Diego, California, United States
University of California, San FranciscoRecruiting
San Francisco, California, United States
Abramson Cancer CenterRecruiting
Philadelphia, Pennsylvania, United States
MD Anderson Cancer CenterRecruiting
Houston, Texas, United States